NCT01030016

Brief Summary

The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started May 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 8, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 10, 2009

Completed
Last Updated

December 15, 2009

Status Verified

May 1, 2009

Enrollment Period

2 years

First QC Date

December 8, 2009

Last Update Submit

December 14, 2009

Conditions

Blood PressureExercise

Keywords

resistance exercisebeta-blockersblood pressure

Outcome Measures

Primary Outcomes (1)

  • blood pressure during resistance exercise

    6 weeks

Study Arms (1)

atenolol

EXPERIMENTAL

subjects received 6 weeks of atenolol

Drug: atenolol

Interventions

atenololDRUG

25 mg/day, twice a day for 6 weeks

Also known as: beta-blockers
atenolol

Eligibility Criteria

Age30 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • hypertension with blood pressure levels below 160/105 mmHg under placebo.
  • age between 30 and 60 years
  • nonobese

You may not qualify if:

  • target organ lesion
  • cardiovascular risk factor
  • cardiovascular disease
  • physically active

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of São Paulo

São Paulo, São Paulo, 05508030, Brazil

Location

MeSH Terms

Conditions

Motor Activity

Interventions

AtenololAdrenergic beta-Antagonists

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

PhenoxypropanolaminesPropanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsPropanolsAminesAdrenergic AntagonistsAdrenergic AgentsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesPhysiological Effects of Drugs

Study Officials

  • Cláudia LM Forjaz, PhD

    University of Sao Paulo

    PRINCIPAL INVESTIGATOR

  • Decio Mion Jr, PhD

    University of Sao Paulo

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 8, 2009

First Posted

December 10, 2009

Study Start

May 1, 2007

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

December 15, 2009

Record last verified: 2009-05

Locations

BR(1)